Highlights Everest Medicines Limited

Equities

1952

KYG3224E1061

Market Closed - Hong Kong S.E. Other stock markets 04:08:23 2024-06-12 am EDT			5-day change	1st Jan Change
19.98 ^HKD	-0.84%		-8.97%	-4.40%

Jun. 10	Transcript : Everest Medicines Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
May. 14	Calliditas Therapeutics Partner Offers Nefecon in China; Shares Rise	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Calliditas Therapeutics Partner Offers Nefecon in China; Shares Rise	May. 14	MT
Everest Medicines Announces Commercial Launch and First Prescription for NEFECON in Mainland China	May. 14	CI
Everest Medicines Commercially Launches Kidney Disease Drug in China	May. 14	MT
Everest Medicines Announces New Drug Application Approval of Velsipity® for Adults with Moderately to Severely Active Ulcerative Colitis in Macau	May. 07	CI
Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients	May. 01	CI
Everest Medicines' Loss Widens in 2023	Apr. 24	MT
Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Everest Medicines Terminates Collaboration with Canada’s Providence for mRNA COVID-19 Vaccines	Feb. 18	MT
Everest Foresees Surge in 2023 Revenue	Jan. 21	MT
Everest Medicines Limited Provides Earning Guidance for the Year Ended 31 December 2023	Jan. 21	CI
Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients	Dec. 26	CI
Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China	Dec. 03	CI
Everest Medicines Reaffirms Revenue Guidance for the Year 2023 and 2024	Nov. 27	CI
Calliditas? Partner Everest Medicines Announces China NMPA?s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy	Nov. 24	CI
Shortened Post-Thanksgiving Session Keeps Exchange-Traded Funds, Equity Futures Muted Pre-Bell Friday	Nov. 24	MT
Calliditas Therapeutics' Partner Secures Approval for Immunoglobulin Nephropathy Treatment in China	Nov. 24	MT
Everest Medicines Announces China NMPA's Approval of Nefecon for the Treatment of Primary IgA Nephropathy	Nov. 24	CI
Chinese Regulator Approves Everest's NDA for Nephropathy Drug	Nov. 24	MT
National Medical Products Administration Approves the New Drug Application for Nefecon for the Treatment of Primary Immunoglobulin A Nephropathy in Adults At Risk of Disease Progress in China	Nov. 23	CI
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy	23-10-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Everest Medicines Limited

Equities

1952

KYG3224E1061

Highlights

Filters